公开(公告)号：EP3793988B1

公开(公告)日：2023-11-15

申请号：EP19728887.1

申请日：2019-05-16

发明人： MORROW, Benjamin, Joseph ,  CAMERINO, Michelle, Ang ,  WALKER, Scott, Raymond ,  STEVENSON, Graeme, Irvine ,  STUPPLE, Paul, Anthony

IPC分类号： C07D333/70 ,  C07D409/12 ,  C07D495/04 ,  C07F9/40 ,  A61P35/00 ,  A61P37/00 ,  A61K31/381

公开(公告)号：EP4249527A1

公开(公告)日：2023-09-27

申请号：EP21894705.9

申请日：2021-11-17

申请人： Kuraray Co., Ltd.

发明人： NOGUCHI, Daiki ,  SASAKI, Yuki ,  FUKUMOTO, Takashi

IPC分类号： C08F20/28 ,  C09K21/14 ,  C08L33/06 ,  C08F2/44 ,  C07F9/32 ,  C07F9/38 ,  C07F9/40 ,  C07F9/53

摘要： Provided is a polymer comprising a structural unit represented by the following general formula (I), a flame-retardant composition comprising the polymer, and a method for producing the polymer.

In the general formula (I), R 1 represents any one selected from the group consisting of an alkyl group having 1 to 18 carbon atoms, an alkenyl group having 2 to 18 carbon atoms, and an aralkyl group having 7 to 18 carbon atoms; R 2 represents a hydrogen atom or a methyl group; R 3 and R 4 each independently represent any one selected from the group consisting of an alkyl group having 1 to 6 carbon atoms, an alkyloxy group having 1 to 6 carbon atoms, an alkenyl group having 2 to 6 carbon atoms, an alkenyloxy group having 2 to 6 carbon atoms, an aralkyl group having 7 to 12 carbon atoms, an aralkyloxy group having 7 to 12 carbon atoms, an aryl group having 6 to 12 carbon atoms, and an aryloxy group having 6 to 12 carbon atoms, and R 3 and R 4 may be bonded to each other; and n is an integer of 0 to 5.

公开(公告)号：EP4161925A1

公开(公告)日：2023-04-12

申请号：EP21822855.9

申请日：2021-06-07

申请人： Viking Therapeutics, Inc.

发明人： LIAN, Brian ,  BARKER, Geoffrey, E. ,  YAGIZ, Kader ,  BARNES, Maureen ,  STEVENS, Erland

IPC分类号： C07D451/06 ,  A61K31/46 ,  A61K31/665 ,  A61K31/675 ,  A61P1/16 ,  C07D403/12 ,  C07F9/40 ,  C07F9/6574

公开(公告)号：EP4103572A1

公开(公告)日：2022-12-21

申请号：EP21754068.1

申请日：2021-02-12

申请人： Bellus Health Cough Inc.

发明人： CHAURET, Nathalie ,  GREEN, Jeremy ,  KRONENTHAL, David, R. ,  VILLENEUVE, Karine

IPC分类号： C07F9/40 ,  C07D265/30 ,  C07D471/04

公开(公告)号：EP4072681A1

公开(公告)日：2022-10-19

申请号：EP20828017.2

申请日：2020-12-09

申请人： Ustav organicke chemie a biochemie AV CR, v.v.i. ,  Mikrobiologicky ustav AV CR, v.v.i. ,  Univerzita Palackého v Olomouci

发明人： REJMAN, Dominik ,  POHL, Radek ,  MOJR, Viktor ,  DO PHAM, Duy Dinh ,  KOLAR, Milan ,  KRASNY, Libor

IPC分类号： A61P31/04 ,  A61K31/663 ,  C07F9/40

公开(公告)号：EP3939964A1

公开(公告)日：2022-01-19

申请号：EP21178147.1

申请日：2009-12-30

申请人： Ardelyx, Inc.

发明人： CHARMOT, Dominique ,  JACOBS, Jeffrey W. ,  LEADBETTER, Michael Robert ,  NAVRE, Marc ,  CARRERAS, Chris ,  BELL, Noah

IPC分类号： C07C311/29 ,  C07D401/12 ,  C07D217/04 ,  C07F9/38 ,  C07F9/40 ,  C07F9/572 ,  C07F9/62 ,  A61K31/18 ,  A61K31/472 ,  A61K31/4725 ,  A61K31/517 ,  A61K31/662 ,  A61K31/675 ,  A61K45/06

摘要： The present disclosure is directed to a pharmaceutical composition comprising a compound of formula (X), in combination with another active agent, and to the use of said composition in methods for the treatment of disorders associated with fluid retention or salt overload or gastrointestinal tract disorders, such as irritable bowel syndrome and constipation associated with cystic fibrosis. The methods generally comprise administering to a mammal in need thereof a pharmaceutical composition comprising such a compound, that is designed to be substantially active in the gastrointestinal (GI) tract to inhibit NHE-mediated antiport of sodium ions and hydrogen ions therein. More particularly, the method comprises administering to a mammal in need thereof a pharmaceutical composition comprising such a compound, that inhibits NHE-3, -2 and/or -8 mediated antiport of sodium and/or hydrogen ions in the GI tract and is designed to be substantially impermeable to the layer of epithelial cells, or more specifically the epithelium of the GI tract. As a result of the compound being substantially impermeable, it is not absorbed and is thus essentially systemically non-bioavailable, so as to limit the exposure of other internal organs (e.g., liver, heart, brain, etc.) thereto.

公开(公告)号：EP3604317B1

公开(公告)日：2021-09-29

申请号：EP18772240.0

申请日：2018-03-20

发明人： ODA, Yuichiro ,  KANEUMI, Yoshiyama

IPC分类号： C07F9/40 ,  C07F9/38 ,  B29C33/60 ,  C09K3/00

公开(公告)号：EP3514160B1

公开(公告)日：2021-08-11

申请号：EP17850874.3

申请日：2017-09-12

发明人： WATANABE, Bunta ,  YOSHIOKA, Ryuzo ,  ISHIDA, Hideaki

IPC分类号： C07F9/40

公开(公告)号：EP3853213A1

公开(公告)日：2021-07-28

申请号：EP19863710.0

申请日：2019-09-19

申请人： Endocyte, Inc.

发明人： LEAMON, Christopher, Paul ,  VLAHOV, Iontcho, Radoslavov

IPC分类号： C07D295/145 ,  C07F9/38 ,  C07F9/40

公开(公告)号：EP2880028B1

公开(公告)日：2020-09-30

申请号：EP13750427.0

申请日：2013-07-31

申请人： Merck Sharp & Dohme Corp.

发明人： HAGMANN, William, K. ,  NARGUND, Ravi, P. ,  BLIZZARD, Timothy, A. ,  JOSIEN, Hubert ,  BIJU, Purakkattle ,  PLUMMER, Christopher, W. ,  DANG, Qun ,  LI, Bing ,  LIN, Linus, S. ,  CUI, Mingxiang ,  HU, Bin ,  HAO, Jinglai ,  CHEN, Zhengxia

IPC分类号： C07D401/14 ,  C07D221/16 ,  C07D401/12 ,  C07F9/40 ,  A61K31/435 ,  A61P3/04 ,  A61P3/06 ,  A61P3/10